Clinitech Laboratory signs MoU with MD Plus Multispeciality ClinicClinitech Laboratory signs MoU with MD Plus Multispeciality Clinic

Introduction

Leading diagnostic services provider signs Memorandum of Understanding with multispeciality clinic for pathology lab operations, sample pickup services and referral radiology support under agreed terms.

Also Read: Gujarat Themis Biosyn to acquire Sanofi anti-TB and anti-infective portfolio

Share price movement of Clinitech

On April 24, 2026, Clinitech Laboratory Ltd opened at ₹41.00, down 2.38% from its previous close of ₹42.00. The stock reached a high of ₹41.00 and a low of ₹40.00. By 16:00 PM, it traded at ₹40.00, a 4.76% decrease, with a market cap of ₹9.13 crore.

Clinitech signs MOU with clinic

Clinitech Laboratory Limited signed a Memorandum of Understanding dated April 25, 2026 with MD Plus Multispeciality Clinic for operating a pathology laboratory and related diagnostic services.

The agreement also includes handling pickup points for pathology samples and providing full referral radiology services under defined terms and conditions between both parties as disclosed.

Stock performance of Clinitech for period of 1 week, 6 months, and 1 year

Clinitech Laboratory Ltd delivered a 1-week return of -12.1%, a 6-month return of -5.93%, and a 1-year return of -11.4%.

Also Read: Tata Power forms new subsidiary TP Urja Limited for new energy initiatives, here is key details

Shareholding pattern of Clinitech

Particulars	Mar 2026	Dec 2025	Sep 2025
Promoter	64%	62%	62%
FII	0.30%	0.30%	0.30%
DII	0.00%	0.00%	0.00%
Public	35.50%	37.30%	38.10%

About Clinitech

Clinitech Laboratory Limited (BSE: 544220) provides NABL accredited healthcare services including pathology testing, diagnostic centres, scan centres, X-ray centres and ECG clinics across locations.

Stay Ahead with the Latest Stock Market Updates – Click Here

Disclaimer: The above article is written for educational purposes, and the companies’ data mentioned in the article may change with respect to time. The securities quoted are exemplary and are not recommendatory.

FAQs